ORATORIO-Cort
We could not find results for this trial
I know where the results areWhat it found
We found no results in the registry or in papers.
This trial finished 2 years ago. We found no results in the registry or in any paper that cites it.
What was tested
Treatment tested
- Ocrelizumab
What it measured
Main measures
Cortical lesion number accumulation
5 years
MRI lesions
Other measures (1)
Cortical lesion number accumulation and disability.
5 years
MRI lesions
Who could take part
Progressive MS · 18 to 65
Inclusion Criteria: * Patient participating in the ORATORIO study * MRI scans available at baseline * Presence of T2-weighted image (WI) (FLAIR, T2/PD), and 2D/3D T1-WI at baseline Exclusion Criteria: - None
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
The goal of this non-interventional, observational study is to determine whether cortical pathology can be slowed down by use of ocrelizumab.
Papers
Loading reviews and guidelines…
Related trials
- C-CAR168, an Autologous Anti-CD20/BCMA Chimeric Antigen R…
Phase 1 / Phase 2 · Not yet recruiting
Still running
- IDP-023 g-NK Cells Plus Ocrelizumab in Patients With Prog…
Phase 1 · Paused
Still running
- Mintaka
Phase 2 · Recruiting
Still running
- The Effect of Rituximab on Cognitive and Hand Functions i…
Phase 2 · Recruiting
Still running
- ORATORIO-CP
Completed
No result found
- LEGATO
Phase 4 · Withdrawn
Stopped early
History
Started
Oct 2023
Main results due
Feb 2024
Finished
Feb 2024
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error